Charles River Laboratories International (NYS: CRL) is expected to report Q2 earnings on Aug. 7. Here's what Wall Street wants to see.
The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will decrease -1.0% and EPS will decrease -5.7%.
The average estimate for revenue is $285.3 million. On the bottom line, the average EPS estimate is $0.66.
Last quarter, Charles River Laboratories International booked revenue of $286.0 million. GAAP reported sales were 0.0% higher than the prior-year quarter's $285.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.70. GAAP EPS of $0.54 for Q1 were 6.9% lower than the prior-year quarter's $0.58 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.4%, 40 basis points better than the prior-year quarter. Operating margin was 15.6%, 60 basis points better than the prior-year quarter. Net margin was 9.2%, 180 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.15 billion. The average EPS estimate is $2.68.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $37.72.
Over the decades, small-cap stocks like Charles River Laboratories International have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
Add Charles River Laboratories International to My Watchlist.
The article Are You Expecting This From Charles River Laboratories International? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.